These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 25261428)

  • 41. Synthetic drugs of abuse.
    Tamama K
    Adv Clin Chem; 2021; 103():191-214. PubMed ID: 34229850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?
    Halter S; Angerer V; Röhrich J; Groth O; Roider G; Hermanns-Clausen M; Auwärter V
    Drug Test Anal; 2019 Feb; 11(2):347-349. PubMed ID: 30468574
    [No Abstract]   [Full Text] [Related]  

  • 43. [Cathinones use in Paris].
    Batisse A; Grégoire M; Marillier M; Fortias M; Djezzar S
    Encephale; 2016 Aug; 42(4):354-60. PubMed ID: 26847479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Drugs scene in Poland from a forensic toxicologist's view].
    Kała M
    Przegl Lek; 2010; 67(8):594-7. PubMed ID: 21387784
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 4,4'-DMAR: chemistry, pharmacology and toxicology of a new synthetic stimulant of abuse.
    Coppola M; Mondola R
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):26-30. PubMed ID: 25819702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GHB and synthetic cathinones: clinical effects and potential consequences.
    Karila L; Reynaud M
    Drug Test Anal; 2011 Sep; 3(9):552-9. PubMed ID: 21960540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones.
    Patrick ME; O'Malley PM; Kloska DD; Schulenberg JE; Johnston LD; Miech RA; Bachman JG
    Drug Alcohol Rev; 2016 Sep; 35(5):586-90. PubMed ID: 26711540
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spice drugs as a new trend: mode of action, identification and legislation.
    Vardakou I; Pistos C; Spiliopoulou Ch
    Toxicol Lett; 2010 Sep; 197(3):157-62. PubMed ID: 20566335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies.
    Assi S; Gulyamova N; Ibrahim K; Kneller P; Osselton D
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part II--piperazines/piperidines, phenylethylamines, tryptamines and miscellaneous 'others'.
    Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
    Ann Agric Environ Med; 2012; 19(4):871-82. PubMed ID: 23311821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New psychoactive substances in Turkey: Narcotics cases assessed by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey.
    Göl E; Çok I
    Forensic Sci Int; 2019 Jan; 294():113-123. PubMed ID: 30502695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New psychoactive substances and their prevalence in the Czech Republic].
    Mravčík V; Běláčková V; Grohmannová K; Zábranský T
    Cas Lek Cesk; 2015; 154(5):216-21. PubMed ID: 26612328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toxicological findings of synthetic cannabinoids in recreational users.
    Kronstrand R; Roman M; Andersson M; Eklund A
    J Anal Toxicol; 2013 Oct; 37(8):534-41. PubMed ID: 23970540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The synthetic cathinone α-pyrrolidinovalerophenone (α-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects.
    Nóbrega L; Dinis-Oliveira RJ
    Drug Metab Rev; 2018 May; 50(2):125-139. PubMed ID: 29540067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland.
    Adamowicz P; Gieroń J; Gil D; Lechowicz W; Skulska A; Tokarczyk B
    Drug Test Anal; 2016 Jan; 8(1):63-70. PubMed ID: 26666629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The toxicology of bath salts: a review of synthetic cathinones.
    Prosser JM; Nelson LS
    J Med Toxicol; 2012 Mar; 8(1):33-42. PubMed ID: 22108839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthetic cathinones (bath salts): legal status and patterns of abuse.
    Fass JA; Fass AD; Garcia AS
    Ann Pharmacother; 2012 Mar; 46(3):436-41. PubMed ID: 22388331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The New Designer Drug Wave: A Clinical, Toxicological, and Legal Analysis.
    Abbott R; Smith DE
    J Psychoactive Drugs; 2015; 47(5):368-71. PubMed ID: 26579784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature.
    Cottencin O; Rolland B; Karila L
    Curr Pharm Des; 2014; 20(25):4106-11. PubMed ID: 24001292
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Designer Drugs 2.0.
    Huestis MA; Tyndale RF
    Clin Pharmacol Ther; 2017 Feb; 101(2):152-157. PubMed ID: 28084644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.